The case for a subunit vaccine against malaria (Q47980314)

7 February 2018

title

The case for a subunit vaccine against malaria (English)

1 reference

7 February 2018

0 references

1 reference

Robin F Anders

1 reference

7 February 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21592861

2 December 2024

publication date

17 May 2011

1 reference

7 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S1471492211000754?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

https://api.elsevier.com/content/article/PII:S1471492211000754?httpAccept=text/plain

2 December 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

2 December 2024

published in

Trends in Parasitology

1 reference

7 February 2018

volume

1 reference

7 February 2018

issue

1 reference

7 February 2018

page(s)

330-334

1 reference

7 February 2018

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

cites work

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Genetically engineered, attenuated whole-cell vaccine approaches for malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Whole parasite blood stage malaria vaccines: a convergence of evidence

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Immunization against blood-stage rodent malaria using purified parasite antigens

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

The future for blood-stage vaccines against malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Advances and challenges in malaria vaccine development

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development.

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

The past decade in malaria synthetic peptide vaccine clinical trials

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Molecular vaccines for malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Merozoite surface proteins of the malaria parasite: The MSP1 complex and the MSP7 family

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Structural studies on Plasmodium vivax merozoite surface protein-1

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

An inhibitory antibody blocks interactions between components of the malarial invasion machinery

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Interaction between Plasmodium falciparum apical membrane antigen 1 and the rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Prime-boost vectored malaria vaccines: progress and prospects

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Reducing empiricism in malaria vaccine design

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Immunization of monkeys against malaria by means of killed parasites with adjuvants.

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Immunization of man against sporozite-induced falciparum malaria

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans.

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2011.04.003

2 December 2024

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018